Covalent kinase inhibitor fragmentation method based on Recap algorithm
The Recap algorithm decomposes covalent kinase inhibitors, screens and optimizes fragments, solves the toxicity and side effects caused by complex structures in the existing technology, achieves more efficient drug research and development and production, reduces costs, and promotes drug chemistry innovation.
Patent Information
- Application Number
- CN202410960107.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-15
AI Technical Summary
The complex structure of existing covalent kinase inhibitors leads to easy reaction with non-target proteins, increasing toxicity and side effects, and the synthesis steps are numerous and costly, and lacks efficient fragmentation methods to optimize structure.
Using the fragmentation method of covalent kinase inhibitors based on the Recap algorithm, the Michael receptor characteristics were screened through collection of molecular structure data, SMARTS pattern matching, and the Recap algorithm decomposes into fragments, screens and filters the fragments, performs biological activity analysis and potential drug design, and optimizes Novel inhibitors.
Reduce off-target effects and side effects, simplify the synthesis process, reduce R&D and production costs, improve drug R&D efficiency and success rate, and the generated fragment library has high structural diversity and promotes drug chemistry innovation.
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medicinal chemistry and chemical informatics, and in particular to a covalent kinase inhibitor fragmentation method based on a Recap algorithm. Background Art
[0002] Covalent kinase inhibitors are a class of drug molecules that inhibit enzyme activity by forming covalent bonds with the active sites of target proteins. This type of inhibitor is highly effective and durable and is widely used in the treatment of cancer and other diseases. Typical covalent kinase inhibitors include imatinib, erlotinib, osimertinib, etc. These drugs form covalent bonds with specific residues of target proteins (such as cystine and lysine), thereby blocking signal transduction pathways and inhibiting the growth and proliferation of tumor cells.
[0003] These covalent inhibitors usually contain Michael acceptor structures, such as enones and enal, which can undergo electrophilic addition reactions with the sulfhydryl or amino groups of the target protein to form stable covalent bonds. The design and synthesis of covalent inhibitors depend on the specific characteristics of their molecular structures, including the selection of active functional groups, molecular skeletons, and substituents.
[0004] Due to the formation mechanism of covalent bonds, many covalent inhibitors easily react with non-target proteins, resulting in off-target effects, increasing the toxicity and side effects of the drugs. This has largely limited the clinical application of covalent inhibitors. Existing covalent inhibitor molecules usually have complex structures, with many synthesis steps and high costs. The complex synthesis path and difficult purification process increase the difficulty of research and development and production.
[0005] In the prior art, the description of product structure and scheme usually includes the chemical structure of various covalent kinase inhibitors and related preparation methods and biological activity data. However, the prior art often fails to provide an efficient fragmentation method to better understand and optimize the structure of these covalent inhibitors. Therefore, those skilled in the art provide a covalent kinase inhibitor fragmentation method based on the Recap algorithm to solve the problems raised in the above background technology. Summary of the invention
[0006] 1. Technical issues to be resolved
[0007] In view of the shortcomings of the prior art, the present invention provides a covalent kinase inhibitor fragmentation method based on the Recap algorithm, which solves the problem that the prior art fails to better understand and optimize the structures of these covalent inhibitors.
[0008] (II) Technical solution
[0009] To achieve the above objectives, the present invention is implemented by the following technical solutions: A covalent kinase inhibitor fragmentation method based on the Recap algorithm, comprising:
[0010] Structure collection: Collect molecular structure data of known covalent kinase inhibitors from scientific literature and databases, including medicinal chemistry journals, patent literature, and public chemical databases;
[0011] Type screening: Using chemical informatics methods, especially SMARTS pattern matching technology, to retrieve and screen covalent inhibitors with Michael acceptor characteristics, the characteristics of the Michael acceptor type include specific electrophilic centers and conjugated systems;
[0012] Recap algorithm fragmentation: The Recap algorithm in RDKit is used to fragment the screened covalent inhibitors. The Recap algorithm decomposes the molecule into several smaller fragments by identifying the chemical bond breakage points in the molecule. The algorithm can efficiently process complex molecular structures and generate a diverse molecular fragment library.
[0013] Fragment filtering: Screen and filter the generated fragments according to preset standards, including:
[0014] The number of heavy atoms, excluding hydrogen atoms, shall not exceed 25;
[0015] The number of loops contained in the fragment does not exceed 3;
[0016] These criteria ensure that the selected fragments have small molecular weight and moderate structural complexity, which are suitable for further drug optimization;
[0017] Data analysis: The retained fragments were further subjected to chemical and biological activity analysis, including calculation of the fragments' Lipninski's five rules, orally active drug properties and other medicinal chemistry properties, and evaluation of the fragments' biological activity and targeting properties through in vitro experiments and computer simulations;
[0018] Potential drug design: Based on the screening analysis results, potential new covalent kinase inhibitors are involved and synthesized, and molecular docking and molecular dynamics simulations are used to further optimize the candidate molecules to improve their selectivity and activity.
[0019] Preferably, the cheminformatics method comprises the following steps:
[0020] S1. Data collection: Collect chemical data from experiments, literature, databases or online resources, including the structure, properties, biological activity and spectral data of compounds;
[0021] S2. Data preprocessing: cleaning the data, removing duplicate, erroneous or incomplete records, standardizing the representation of compounds, using SM I LES or l nch l format, data conversion, converting compound structures into molecular descriptors;
[0022] S3. Molecular descriptor calculation, calculate the physicochemical properties, topological index and electronic property descriptors of molecules. The descriptors can be 2D or 3D and are used to characterize the structure and properties of molecules;
[0023] S4. Data modeling and analysis, applying statistical and machine learning methods to establish quantitative structure-activity relationship models, perform chemometric analysis, conduct molecular docking and virtual screening, and predict the interaction between molecules and biological targets;
[0024] S5. Model validation and optimization: Use cross-validation to validate the model's predictive ability and adjust model parameters to optimize model performance.
[0025] S6. Interpretation and application of results: interpret model results, extract chemical knowledge, and apply models to design new compounds, predict activity, and discover drugs;
[0026] S7. Data management and sharing, use databases and data warehouses to manage chemical data, and share data and models through network platforms.
[0027] Preferably, the Recap algorithm fragmentation comprises the following steps:
[0028] S1. Molecular input. First, the molecular structure of the covalent inhibitor is input into the Recap algorithm in SMILES or other chemical informatics formats.
[0029] S2. Disassembly process, the Recap algorithm disassembles the input covalent inhibitor molecule through a series of transformation and decomposition steps, which may include identifying and cutting specific chemical bonds in the molecule, which may be used as cutting points for reverse synthesis during the synthesis process;
[0030] S3. Generate fragments. After the disassembly process is completed, the Recap algorithm will generate a series of molecular fragments. These fragments represent the components of the original covalent inhibitor molecules, which can be single functional groups, ring structures or other chemical structures;
[0031] S4. Data structure. The Recap algorithm organizes and stores the disassembly process and results in the form of a tree data structure. In this process, the original molecule is regarded as the root node, the disassembled molecule is regarded as the parent node, the disassembled molecular fragments are regarded as nodes, and the molecular fragments that cannot be further disassembled are regarded as leaf nodes.
[0032] S5. Information extraction, through the interface provided by the Recap algorithm, the information of molecular fragments can be extracted, including their SM ILES representation, molecular weight and functional group properties;
[0033] S6. Analysis and application. The obtained molecular fragments can be used for further analysis, including evaluating their biological activity, drug design or synthesis of new compounds. In the study of covalent inhibitors, these fragments can be used to understand the interaction mechanism between inhibitors and target proteins, or to design new covalent inhibitors.
[0034] (III) Beneficial effects
[0035] The present invention provides a covalent kinase inhibitor fragmentation method based on the Recap algorithm.
[0036] Beneficial effects:
[0037] 1. In the present invention, covalent inhibitors with higher selectivity are designed through fine fragmentation and screening, which reduces off-target effects and side effects. The screened fragments have smaller molecular structures, which simplifies the synthesis process of new inhibitors and reduces R&D and production costs.
[0038] 2. In the present invention, the systematic fragmentation analysis method accelerates the discovery and optimization process of new covalent inhibitors, improves the efficiency and success rate of drug research and development, and the generated fragment library has high structural diversity, which provides rich options for the design of new drugs and promotes innovation in the field of medicinal chemistry. DETAILED DESCRIPTION
[0039] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0040] Embodiment 1:
[0041] The embodiment of the present invention provides a covalent kinase inhibitor fragmentation method based on the Recap algorithm, comprising:
[0042] Structure collection: Collect molecular structure data of known covalent kinase inhibitors from scientific literature and databases, including medicinal chemistry journals, patent literature, and public chemical databases;
[0043] Type screening: Using chemical informatics methods, especially SMARTS pattern matching technology, to retrieve and screen covalent inhibitors with Michael acceptor characteristics, the characteristics of the Michael acceptor type include specific electrophilic centers and conjugated systems;
[0044] Recap algorithm fragmentation: The Recap algorithm in RDKit is used to fragment the screened covalent inhibitors. The Recap algorithm decomposes the molecule into several smaller fragments by identifying the chemical bond breakage points in the molecule. The algorithm can efficiently process complex molecular structures and generate a diverse molecular fragment library.
[0045] Fragment filtering: Screen and filter the generated fragments according to preset standards, including:
[0046] The number of heavy atoms, excluding hydrogen atoms, shall not exceed 25;
[0047] The number of loops contained in the fragment does not exceed 3;
[0048] These criteria ensure that the selected fragments have small molecular weight and moderate structural complexity, which are suitable for further drug optimization;
[0049] Data analysis: The retained fragments were further subjected to chemical and biological activity analysis, including calculation of the fragments' Lipninski's five rules, orally active drug properties and other medicinal chemistry properties, and evaluation of the fragments' biological activity and targeting properties through in vitro experiments and computer simulations;
[0050] Potential drug design: Based on the screening analysis results, potential new covalent kinase inhibitors are involved and synthesized, and molecular docking and molecular dynamics simulations are used to further optimize the candidate molecules to improve their selectivity and activity.
[0051] The cheminformatics approach includes the following steps:
[0052] S1. Data collection: Collect chemical data from experiments, literature, databases or online resources, including the structure, properties, biological activity and spectral data of compounds;
[0053] S2. Data preprocessing: cleaning the data, removing duplicate, erroneous or incomplete records, standardizing the representation of compounds, using SMILES or l nch l format, data conversion, converting compound structures into molecular descriptors;
[0054] S3. Molecular descriptor calculation, calculate the physicochemical properties, topological index and electronic property descriptors of molecules. The descriptors can be 2D or 3D and are used to characterize the structure and properties of molecules;
[0055] S4. Data modeling and analysis, applying statistical and machine learning methods to establish quantitative structure-activity relationship models, perform chemometric analysis, conduct molecular docking and virtual screening, and predict the interaction between molecules and biological targets;
[0056] S5. Model validation and optimization: Use cross-validation to validate the model's predictive ability and adjust model parameters to optimize model performance.
[0057] S6. Interpretation and application of results: interpret model results, extract chemical knowledge, and apply models to design new compounds, predict activity, and discover drugs;
[0058] S7. Data management and sharing, use databases and data warehouses to manage chemical data, and share data and models through network platforms.
[0059] Recap algorithm fragmentation includes the following steps:
[0060] S1. Molecular input, first, the molecular structure of the covalent inhibitor is input into the Recap algorithm in SMILES or other chemical informatics formats;
[0061] S2. Disassembly process, the Recap algorithm disassembles the input covalent inhibitor molecule through a series of transformation and decomposition steps, which may include identifying and cutting specific chemical bonds in the molecule, which may be used as cutting points for reverse synthesis during the synthesis process;
[0062] S3. Generate fragments. After the disassembly process is completed, the Recap algorithm will generate a series of molecular fragments. These fragments represent the components of the original covalent inhibitor molecules, which can be single functional groups, ring structures or other chemical structures;
[0063] S4. Data structure. The Recap algorithm organizes and stores the disassembly process and results in the form of a tree data structure. In this process, the original molecule is regarded as the root node, the disassembled molecule is regarded as the parent node, the disassembled molecular fragments are regarded as nodes, and the molecular fragments that cannot be further disassembled are regarded as leaf nodes.
[0064] S5. Information extraction: Through the interface provided by the Recap algorithm, the information of molecular fragments can be extracted, including their SMILES representation, molecular weight and functional group properties;
[0065] S6. Analysis and application. The obtained molecular fragments can be used for further analysis, including evaluating their biological activity, drug design or synthesis of new compounds. In the study of covalent inhibitors, these fragments can be used to understand the interaction mechanism between inhibitors and target proteins, or to design new covalent inhibitors.
[0066] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A covalent kinase inhibitor fragmentation method based on the Recap algorithm, characterized in that: include: Structure collection: Collect molecular structure data of known covalent kinase inhibitors from scientific literature and databases, including medicinal chemistry journals, patent literature, and public chemical databases; Type screening: Using chemical informatics methods, especially SMARTS pattern matching technology, to retrieve and screen covalent inhibitors with Michael acceptor characteristics, the characteristics of the Michael acceptor type include specific electrophilic centers and conjugated systems; Recap algorithm fragmentation: The Recap algorithm in RDKit is used to fragment the screened covalent inhibitors. The Recap algorithm decomposes the molecule into several smaller fragments by identifying the chemical bond breakage points in the molecule. The algorithm can efficiently process complex molecular structures and generate a diverse molecular fragment library. Fragment filtering: Screen and filter the generated fragments according to preset standards, including: The number of heavy atoms (excluding hydrogen atoms) does not exceed 25; The number of loops contained in the fragment does not exceed 3; These criteria ensure that the selected fragments have small molecular weight and moderate structural complexity, which are suitable for further drug optimization; Data analysis: The retained fragments were further subjected to chemical and biological activity analysis, including calculation of the fragments’ Lipinski’s five rules (characteristics of orally active drugs) and other medicinal chemistry properties, and evaluation of the fragments’ biological activity and targeting properties through in vitro experiments and computer simulations; Potential drug design: Based on the screening analysis results, potential new covalent kinase inhibitors are involved and synthesized, and molecular docking and molecular dynamics simulations are used to further optimize the candidate molecules to improve their selectivity and activity.
2. The covalent kinase inhibitor fragmentation method based on the Recap algorithm according to claim 1, characterized in that: The cheminformatics method comprises the following steps: S1. Data collection: Collect chemical data from experiments, literature, databases or online resources, including the structure, properties, biological activity and spectral data of compounds; S2. Data preprocessing: cleaning the data, removing duplicate, erroneous or incomplete records, standardizing the representation of compounds, using SMILES or lnchl format, data conversion, converting compound structures into molecular descriptors; S3. Molecular descriptor calculation, calculate the physicochemical properties, topological index and electronic property descriptors of molecules. The descriptors can be 2D or 3D and are used to characterize the structure and properties of molecules; S4. Data modeling and analysis, applying statistical and machine learning methods to establish quantitative structure-activity relationship models, perform chemometric analysis, conduct molecular docking and virtual screening, and predict the interaction between molecules and biological targets; S5. Model validation and optimization: Use cross-validation to validate the model's predictive ability and adjust model parameters to optimize model performance. S6. Interpretation and application of results: interpret model results, extract chemical knowledge, and apply models to design new compounds, predict activity, and discover drugs; S7. Data management and sharing, use databases and data warehouses to manage chemical data, and share data and models through network platforms.
3. The covalent kinase inhibitor fragmentation method based on the Recap algorithm according to claim 1, characterized in that: The Recap algorithm fragmentation includes the following steps: S1. Molecular input, first, the molecular structure of the covalent inhibitor is input into the Recap algorithm in SMILES or other chemical informatics formats; S2. Disassembly process, the Recap algorithm disassembles the input covalent inhibitor molecule through a series of transformation and decomposition steps, which may include identifying and cutting specific chemical bonds in the molecule, which may be used as cutting points for reverse synthesis during the synthesis process; S3. Generate fragments. After the disassembly process is completed, the Recap algorithm will generate a series of molecular fragments. These fragments represent the components of the original covalent inhibitor molecules, which can be single functional groups, ring structures or other chemical structures; S4. Data structure. The Recap algorithm organizes and stores the disassembly process and results in the form of a tree data structure. In this process, the original molecule is regarded as the root node, the disassembled molecule is regarded as the parent node, the disassembled molecular fragments are regarded as nodes, and the molecular fragments that cannot be further disassembled are regarded as leaf nodes. S5. Information extraction: Through the interface provided by the Recap algorithm, the information of molecular fragments can be extracted, including their SMI LES representation, molecular weight and functional group properties; S6. Analysis and application. The obtained molecular fragments can be used for further analysis, including evaluating their biological activity, drug design or synthesis of new compounds. In the study of covalent inhibitors, these fragments can be used to understand the interaction mechanism between inhibitors and target proteins, or to design new covalent inhibitors.
Citation Information
Patent Citations
8-amino-3-substituted-imidazo[1,5-a]pyrazine and use thereof as inhibitors of bruton's tyrosine kinase
CA3143428A1
Computer screening method for small molecular covalent inhibitors and application of method to screening of S-adenosylmethionine decarboxylase covalent inhibitors
CN106407739A
Organic molecule virtual screening space construction method based on chemical feasibility verification
CN116110514A
Compositions comprising exemestane and novel methods of use
US20150025049A1
Cited By
Drug structure-activity relationship analysis method and device based on multi-level structure
CN120280031A
